PMID: 9533770Apr 9, 1998Paper

Interleukin-2 gene therapy of surgical minimal residual tumour disease

International Journal of Cancer. Journal International Du Cancer
V VlkV Sobota

Abstract

Our study was designed to examine the effects of IL-2 gene therapy in a surgical minimal residual tumour disease (SMRTD). Mice were inoculated s.c. with methylcholanthrene (MC)-induced MC12 sarcoma cells. When the tumours reached 8 to 12 mm in diameter, they were excised, either completely ("microscopic SMRTD") or incompletely ("macroscopic SMRTD"). On day 90 after surgery, the tumour recurrence rate in untreated mice with microscopic SMRTD was approximately 30%, whereas in those with macroscopic SMRTD it was 75%. After surgery, experimental mice were treated with 2 types of irradiated, IL-2 gene-modified, IL-2-producing tumour cell vaccine. One type of vaccine was derived from the MC12 sarcoma cells (MC12-1L2/IV-3); the other type was derived from an unrelated X63-Ag8.653 plasmacytoma (X63-m-IL-2). Both types of vaccine failed to cure the macroscopic SMRTD. Whereas the X63-m-IL-2 vaccine was also ineffective in the microscopic SMRTD, the MC12-IL2/IV-3 vaccine was capable of preventing growth in all but one mouse (1164) with microscopic SMRTD when administered 2 to 5 days after surgery. If the vaccination took place 2 days before surgery or later than 5 days after surgery, the therapeutic activity was lost. Vaccination with irr...Continue Reading

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S A Rosenberg
May 1, 1991·The Journal of Urology·J D Fleischmann, B Kim
Jan 1, 1990·Methods in Cell Biology·P K HoranS E Slezak
Oct 1, 1990·The Journal of Experimental Medicine·B GansbacherE Gilboa
Jan 1, 1985·Cancer Immunology, Immunotherapy : CII·J BubeníkA Toulcová
Jan 1, 1983·Cancer Immunology, Immunotherapy : CII·J BubeníkJ Neuwirt
Jan 1, 1995·Journal of Cancer Research and Clinical Oncology·J BubeníkM Indrová
Jan 12, 1996·Science·R M Zinkernagel
Jan 1, 1997·Journal of the National Cancer Institute·J A Roth, R J Cristiano

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.